Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals (CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics (DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...
BIGGEST MOVERS FROM THIS WEEK
The CEO of $CNS Pharmaceuticals (CNSP.US)$ has disclosed the acquisition of 15,000 shares at a mean price of $0.69 per share. Shares closed the week down 20% at $1.89.
$Dermata Therapeutics (DRMA.US)$ received FDA approval for its proposed protocols and regulations for the Phase 3 clin...
6
1
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
$Merck & Co (MRK.US)$ said Sunday it has agreed to acquire all of the outstanding shares of $Prometheus Biosciences (RXDX.US)$ for $200 per share in cash, for a total equity value of about $10.8 billion.
Under the terms of the deal, Merck will acquire Prometheus through a subsidiary. The deal is expected to close in Q3, s...
$Merck & Co (MRK.US)$ said Sunday it has agreed to acquire all of the outstanding shares of $Prometheus Biosciences (RXDX.US)$ for $200 per share in cash, for a total equity value of about $10.8 billion.
Under the terms of the deal, Merck will acquire Prometheus through a subsidiary. The deal is expected to close in Q3, s...
12
BioPharm Insight US
commented on
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
The FDA has granted Emergency Use Authorization (EUA) for Gohibic (vilobelimab) to $InflaRx (IFRX.US)$ for the treatment of COVID-19 in hospitalized adults, provided it is initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (E...
BIGGEST MOVERS FROM THIS WEEK
The FDA has granted Emergency Use Authorization (EUA) for Gohibic (vilobelimab) to $InflaRx (IFRX.US)$ for the treatment of COVID-19 in hospitalized adults, provided it is initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (E...
14
2
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Next week big pharma companies such as $Biogen (BIIB.US)$ , $Sage Therapeutics (SAGE.US)$ , and $Ironwood Pharmaceuticals (IRWD.US)$ will release their quarterly earnings report.
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma (HILS.US)$ shares continued to trade up this week after it announced initial results from a study...
Next week big pharma companies such as $Biogen (BIIB.US)$ , $Sage Therapeutics (SAGE.US)$ , and $Ironwood Pharmaceuticals (IRWD.US)$ will release their quarterly earnings report.
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma (HILS.US)$ shares continued to trade up this week after it announced initial results from a study...
7
3
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma (HILS.US)$ shares closed the week up 85% at $1.11 after it entered into a an exclusive license agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. The deal allows Hillstream to develop anti-MUC1-C antibodies to selectively deli...
BIGGEST MOVERS FROM THIS WEEK
$Hillstream BioPharma (HILS.US)$ shares closed the week up 85% at $1.11 after it entered into a an exclusive license agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein. The deal allows Hillstream to develop anti-MUC1-C antibodies to selectively deli...
6
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
BIGGEST MOVERS FROM THIS WEEK
$Vivos Therapeutics (VVOS.US)$ +240% (a FDA 510(k) clearance for its proprietary DNA appliance (daytime-nighttime appliance). The device clearance gives rise to an entirely new treatment regimen for mild-to-moderate obstructive sleep apnea (OSA).)
$Lucira Health (LHDX.US)$ submitted an Emergency U...
BIGGEST MOVERS FROM THIS WEEK
$Vivos Therapeutics (VVOS.US)$ +240% (a FDA 510(k) clearance for its proprietary DNA appliance (daytime-nighttime appliance). The device clearance gives rise to an entirely new treatment regimen for mild-to-moderate obstructive sleep apnea (OSA).)
$Lucira Health (LHDX.US)$ submitted an Emergency U...
10
7
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
$Amgen (AMGN.US)$ Inc. is in advanced talks to buy drug company $Horizon Therapeutics (HZNP.US)$, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
$ROCHESTER RESOURCES LTD (RCTFF.US)$Holding AG presented new data from a ...
$Amgen (AMGN.US)$ Inc. is in advanced talks to buy drug company $Horizon Therapeutics (HZNP.US)$, according to people familiar with the matter, in a takeover likely to be valued at well over $20 billion and mark the largest healthcare merger of the year.
$ROCHESTER RESOURCES LTD (RCTFF.US)$Holding AG presented new data from a ...
16
2
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
The American Society of Hematology (ASH) Annual Meeting is set to begin this week. This conference, which carries from December 10 to the 13th, is an excellent opportunity for companies to present new or updated data from ongoing trials. This week's watchlist includes presentations scheduled for t...
Top Medical News of the Week
The American Society of Hematology (ASH) Annual Meeting is set to begin this week. This conference, which carries from December 10 to the 13th, is an excellent opportunity for companies to present new or updated data from ongoing trials. This week's watchlist includes presentations scheduled for t...
5
BioPharm Insight US
reacted to and commented on
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
$Imago BioSciences (IMGO.US)$ traded higher after it was announced that it will be acquired by $Merck & Co (MRK.US)$ for $36 per share in cash. The deal totals an estimated $1.35 billion.
$Palisade Bio (PALI.US)$ announced the FDA granted Fast Track designation to LB1148 for the acceleration of t...
Top Medical News of the Week
$Imago BioSciences (IMGO.US)$ traded higher after it was announced that it will be acquired by $Merck & Co (MRK.US)$ for $36 per share in cash. The deal totals an estimated $1.35 billion.
$Palisade Bio (PALI.US)$ announced the FDA granted Fast Track designation to LB1148 for the acceleration of t...
10
2
Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
A variant of the flu that hits kids and seniors worse than other strains of the virus is dominant in the U.S. right now, setting the country up for a potentially bad flu season. The flu hospitalization rate has surged to a decade high this season.
$Pfizer (PFE.US)$ said its omicron booster trigge...
Top Medical News of the Week
A variant of the flu that hits kids and seniors worse than other strains of the virus is dominant in the U.S. right now, setting the country up for a potentially bad flu season. The flu hospitalization rate has surged to a decade high this season.
$Pfizer (PFE.US)$ said its omicron booster trigge...
5
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)